Neurology

Myrtelle, rAAVen Therapeutics announce partnership to develop novel gene therapy vectors

Myrtelle and rAAVen Therapeutics have announced a partnership to develop novel recombinant adeno-associated virus (rAAV) vectors to progress gene therapy treatments for diseases of the central nervous system (CNS) in which myelin is impacted.

Vistagen agrees to acquire Pherin Pharmaceuticals

Vistagen has signed a definitive agreement for the acquisition of clinical-stage drug development firm Pherin Pharmaceuticals.

KemPharm receives Orphan Drug Designation for idiopathic hypersomnia prodrug

KemPharm has received the Orphan Drug Designation from the US Food and Drug Administration (FDA) for serdexmethylphenidate (SDX) to treat rare neurological sleep disorder, idiopathic hypersomnia (IH).

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Marinus Pharmaceuticals has signed a collaboration and supply agreement with Tenacia Biotechnology (Shanghai), a China-based biotechnology company focused on the development of innovative treatments for central nervous system (CNS) disorders.

FDA approves Axsome Therapeutics’ oral antidepressant Auvelity

The US Food and Drug Administration (FDA) has approved Axsome Therapeutics’ Auvelity (dextromethorphan HBr -bupropion HCl) to treat adult patients with major depressive disorder (MDD).

Acadia Pharmaceuticals receives CRL for sNDA for NUPLAZID to treat ADP

Acadia Pharmaceuticals has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) on its supplemental New Drug Application (sNDA) for NUPLAZID (pimavanserin).

SK Biopharmaceuticals signs licensing agreement with Eurofarma for cenobamate

SK Biopharmaceuticals has signed a licensing agreement with Eurofarma, a Brazilian pharmaceutical company, to develop and commercialise cenobamate in Latin America for epilepsy treatment.

SwanBio raises $56m to advance new gene therapies for neurological conditions

SwanBio Therapeutics, a gene therapy company, has raised $56m through Series B financing round to advance gene therapies for neurological conditions.

Apnimed raises funding to advance new treatments development for OSA

Apnimed has raised $62.5m funding in a Series C round led by new investor Sectoral Asset Management to advance new pharmaceutical treatments development for obstructive sleep apnea (OSA) and related sleep disorders.